Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
about
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSInfluence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virusMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsA Review of Management of Inflammation in the HIV PopulationSwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeHIV integrase inhibitors: a new era in the treatment of HIV.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Inflammation, Immune Activation, and Antiretroviral Therapy in HIVSwitch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.Residual immune dysregulation syndrome in treated HIV infection.Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients.Can early therapy reduce inflammation?HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individualsComparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Epidemiology and management of antiretroviral-associated cardiovascular disease.Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort StudyDifferential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Factors Associated With Plasma IL-6 Levels During HIV Infection.Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV InfectionComparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.Raltegravir as antiretroviral therapy in HIV/AIDS.Drug safety profile of integrase strand transfer inhibitors.Switch strategies in antiretroviral therapy regimens.Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4).Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.Combination antiretroviral therapy and cancer risk.Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals.Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients.Effect of adiponectin-encoding gene ADIPOQ single nucleotide polymorphisms +45 and +276 on serum lipid levels after antiretroviral therapy in Japanese patients with HIV-1-infection.Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viraemia.
P2860
Q26783253-7CA05859-F6C0-44ED-BE0B-1DB1E4506D75Q26851535-DE5DD7C3-4E0A-4721-B3FF-33CBF4C96605Q27024262-B4D7F01D-6C3C-490A-A23C-5D23324FA61DQ28078962-749741C8-BCD3-4724-81A6-7AACD861B134Q28553066-A61904C7-5A4D-4CB4-BB5D-AF46384D44A4Q30956943-05EA1067-588E-451E-B274-C484C1671BF4Q33649200-B72D5ABF-6735-41C9-A1E0-50884E32A879Q33912595-5CACE9CA-00AE-4884-9329-44D1ED3DA503Q33934080-35593B02-2EEF-456D-B287-78B3D17975E6Q34020121-FF2DF651-3158-4BE5-9A06-113F53AD3084Q34061952-E053C35B-5266-4107-BF78-EB48F7169121Q34159822-13654582-4405-4A91-A519-8E04BBB7BB37Q34348888-6802C520-3C14-4A7F-BADF-4DA33BAFC01FQ34612385-E83F4C97-9DBC-49F0-8AD0-F7028A1DE860Q35109483-66D06DE9-3606-46E6-8140-D57744CCFAFCQ35338096-F5F9E355-3CDD-4B2E-A7F7-6CA88DB9B90FQ35814594-9EC855C9-5ECA-4767-AED8-CB0D11ED75EEQ35965242-1EAB316D-4622-4CAB-A7AA-A9CA0BCFC112Q35974422-6359DE50-3694-4594-BE5F-31A1817B071AQ36139186-C7AD0564-E1F6-4F1E-9668-048FCA0ACD65Q36654972-753B9912-3EFA-4E9C-8750-1A34D2C8A4CAQ36822866-BCA81478-1D4B-466D-AAE6-1D173684A6E0Q38168587-B33E88C9-0612-4F48-892F-0C32C657B0ECQ38193524-F8165E59-7DD6-4819-B512-945E032DDD59Q38235295-25D64FB9-99F7-44D0-A8C4-1170211E2EBCQ38406037-3CB2182A-37CA-40A1-AB69-D11191AA4D1FQ38620257-7274BC27-9767-4B1C-B629-D25CA6FC7615Q38734899-2D7E3D5B-7F72-4FC2-9A1C-DFE01B64284CQ38813848-26CFE77D-9998-4A06-BFA0-60DB1E12B76FQ38984209-FE3DD6AB-88D8-41F5-AFC2-B427D7A9CC05Q40051462-BF6D0006-8150-41B4-8513-6139B1BBDAC5Q40100018-C452F247-BD37-4D5B-B17A-793FAD33DE9FQ40145206-2CB8DEF2-E077-4E15-B9BA-ECCABABC1F9FQ40277330-D3A78E96-329E-46B5-9602-E1B49FF6476EQ40504034-5DF29D41-B7E1-4E6A-BBCE-44F4F9074FF1Q40529577-2E0661D7-2BA8-4781-A7FE-CC3A5C0B7417Q40531468-22FE0B77-469C-43F2-84EB-A8C677E6A642Q40810270-9AAC8DA6-B63F-48C0-AD5A-421DA3C59E9CQ41217657-1BE01C6E-A083-463C-8FFA-7889BE7C4268Q41663865-67346603-E94C-4672-83F5-2768ED45BF89
P2860
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@en
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@nl
type
label
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@en
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@nl
prefLabel
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@en
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@nl
P2093
P1433
P1476
Changes in cardiovascular biom ...... ase inhibitors to raltegravir.
@en
P2093
Antonio Antela
Daniel Podzamczer
Esteban Martínez
Felix Gutierrez
Ignacio Perez
Josep M Llibre
José M Gatell
Juan Berenguer
Judit Pich
Pere Domingo
P304
P356
10.1097/QAD.0B013E328359F29C
P407
P577
2012-11-01T00:00:00Z